146 related articles for article (PubMed ID: 28807232)
1. Ovarian cancer: Novel molecular aspects for clinical assessment.
Palmirotta R; Silvestris E; D'Oronzo S; Cardascia A; Silvestris F
Crit Rev Oncol Hematol; 2017 Sep; 117():12-29. PubMed ID: 28807232
[TBL] [Abstract][Full Text] [Related]
2. Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan J; Lima JP; Dumas L; Banerjee S
Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
[TBL] [Abstract][Full Text] [Related]
3. New perspectives in ovarian cancer treatment.
Schmid BC; Oehler MK
Maturitas; 2014 Feb; 77(2):128-36. PubMed ID: 24380827
[TBL] [Abstract][Full Text] [Related]
4. Current and emerging treatment options in the management of advanced ovarian cancer.
Rodriguez-Freixinos V; Mackay HJ; Karakasis K; Oza AM
Expert Opin Pharmacother; 2016 Jun; 17(8):1063-76. PubMed ID: 26918413
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review.
Muinao T; Deka Boruah HP; Pal M
Exp Cell Res; 2018 Jan; 362(1):1-10. PubMed ID: 29079264
[TBL] [Abstract][Full Text] [Related]
6. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
7. Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy.
Sharrow AC; Perkins B; Collector MI; Yu W; Simons BW; Jones RJ
Gynecol Oncol; 2016 Aug; 142(2):341-8. PubMed ID: 27017984
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
11. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.
Liu J; Matulonis UA
Clin Cancer Res; 2014 Oct; 20(20):5150-6. PubMed ID: 25320365
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer.
Markowska A; Sajdak S; Markowska J; Huczyński A
Eur J Med Chem; 2017 Dec; 142():87-94. PubMed ID: 28651817
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapies for Ovarian Cancer.
Grunewald T; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
[TBL] [Abstract][Full Text] [Related]
14. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
[TBL] [Abstract][Full Text] [Related]
15. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer: diagnostic, biological and prognostic aspects.
Davidson B; Tropé CG
Womens Health (Lond); 2014 Sep; 10(5):519-33. PubMed ID: 25335543
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Johnson N; Liao JB
Int J Gynecol Cancer; 2017 Nov; 27(9S Suppl 5):S14-S19. PubMed ID: 29040190
[TBL] [Abstract][Full Text] [Related]
18. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets.
Ahmed N; Abubaker K; Findlay JK
Mol Aspects Med; 2014 Oct; 39():110-25. PubMed ID: 23811037
[TBL] [Abstract][Full Text] [Related]
20. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
